Cargando…
Identification of a novel oncogenic mutation of FGFR4 in gastric cancer
Gastric cancer remains one of the leading causes of cancer death worldwide. Despite intensive investigations of treatments over the past three decades, the poor prognosis of patients with unresectable advanced or recurrent gastric cancer has not significantly changed, and improved therapies are requ...
Autores principales: | Futami, Takashi, Kawase, Tatsuya, Mori, Kenichi, Asaumi, Makoto, Kihara, Rumi, Shindoh, Nobuaki, Kuromitsu, Sadao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787178/ https://www.ncbi.nlm.nih.gov/pubmed/31601997 http://dx.doi.org/10.1038/s41598-019-51217-6 |
Ejemplares similares
-
ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017) -
Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019) -
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
por: Mori, Masamichi, et al.
Publicado: (2017) -
A Japanese familial case of hypochondroplasia with a novel mutation in
FGFR3
por: Nagahara, Keiko, et al.
Publicado: (2016) -
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)